RESUMEN
BACKGROUND & AIMS: Despite the growing recognition of duodenal alterations in the pathophysiology of functional dyspepsia (FD), the effect and mechanism of proton pump inhibitors (PPIs) or first-line therapy remain unclear. We studied duodenal and systemic alterations in relation to PPI therapy in patients with FD and healthy volunteers (HVs). METHODS: We performed a prospective interventional study assessing symptoms (Patient Assessment of Gastrointestinal Symptom Severity Index), duodenal alterations, and systemic factors in patients with FD ("FD-starters") and HVs before and after PPI therapy (pantoprazole 40 mg once daily for 4 weeks). Duodenal mucosal eosinophils, mast cells and permeability were quantified. Luminal pH and bile salts were determined in duodenal aspirates. Procedures were also performed in PPI-refractory patients with FD ("FD-stoppers") before and 8 weeks after PPI withdrawal. Between- and within-group changes from baseline and associations with duodenal or systemic factors were analyzed using linear mixed models. RESULTS: The study was completed by 30 HV, 27 FD-starters, and 18 FD-stoppers. Symptoms and duodenal eosinophils, mast cells (all, P < .0001), and paracellular passage (P = .02) were significantly higher in FD-starters vs HVs and reduced with PPI therapy. Symptoms and duodenal immune cells also decreased in FD-stoppers off PPIs. In contrast, immune cells and permeability increased in HVs on PPIs. Dyspeptic symptoms correlated with eosinophils before and during PPI therapy, and increased eosinophils and permeability in HVs on PPIs were associated with changes in bile salts. CONCLUSIONS: We provide the first prospective evidence for eosinophil-reducing effects as a therapeutic mechanism of PPIs in FD, with differential effects in HVs pointing to a role of luminal changes. ClinicalTrials.gov, Number: NCT03545243.
Asunto(s)
Enfermedades Duodenales/tratamiento farmacológico , Duodeno/efectos de los fármacos , Dispepsia/tratamiento farmacológico , Eosinofilia/tratamiento farmacológico , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Mucosa Intestinal/efectos de los fármacos , Mastocitos/efectos de los fármacos , Pantoprazol/uso terapéutico , Inhibidores de la Bomba de Protones/uso terapéutico , Adulto , Bélgica , Ácidos y Sales Biliares/metabolismo , Estudios de Casos y Controles , Enfermedades Duodenales/diagnóstico , Enfermedades Duodenales/inmunología , Enfermedades Duodenales/metabolismo , Duodeno/inmunología , Duodeno/metabolismo , Dispepsia/diagnóstico , Dispepsia/inmunología , Dispepsia/metabolismo , Eosinofilia/diagnóstico , Eosinofilia/inmunología , Eosinofilia/metabolismo , Femenino , Humanos , Mediadores de Inflamación/metabolismo , Enfermedades Inflamatorias del Intestino/diagnóstico , Enfermedades Inflamatorias del Intestino/inmunología , Enfermedades Inflamatorias del Intestino/metabolismo , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Masculino , Mastocitos/inmunología , Mastocitos/metabolismo , Pantoprazol/efectos adversos , Permeabilidad , Estudios Prospectivos , Inhibidores de la Bomba de Protones/efectos adversos , Factores de Tiempo , Resultado del TratamientoAsunto(s)
COVID-19/patología , Enfermedades Duodenales/patología , Enteritis/diagnóstico , Mucosa Intestinal/patología , Lupus Eritematoso Sistémico/diagnóstico , Microvasos/patología , Microangiopatías Trombóticas/patología , Adulto , COVID-19/complicaciones , COVID-19/diagnóstico por imagen , COVID-19/inmunología , Lectina de Unión a Manosa de la Vía del Complemento/inmunología , Proteínas del Sistema Complemento/inmunología , Diagnóstico Diferencial , Enfermedades Duodenales/diagnóstico por imagen , Enfermedades Duodenales/etiología , Enfermedades Duodenales/inmunología , Edema/diagnóstico por imagen , Edema/etiología , Endoscopía del Sistema Digestivo , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Humanos , Inmunohistoquímica , Mucosa Intestinal/irrigación sanguínea , Isquemia/patología , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/inmunología , Necrosis , SARS-CoV-2 , Microangiopatías Trombóticas/diagnóstico , Microangiopatías Trombóticas/etiología , Microangiopatías Trombóticas/inmunología , Tomografía Computarizada por Rayos XRESUMEN
Malakoplakia is a rare, granulomatous disorder that is typically triggered by infections in immunocompromised patients. Although it most commonly affects the urinary tract, cases may occasionally occur in the gastrointestinal tract. There are case reports of malakoplakia of the pancreas with associated pathologic description, but none with detailed imaging and endoscopic findings. In addition, description of magnetic resonance imaging characteristics of mass-forming malakoplakia in the literature is sparse. We present a case of pancreaticoduodenal malakoplakia in an immunocompromised patient, including detailed description of magnetic resonance imaging, computed tomography, and endoscopic findings with radiology-pathology correlation. Classic pathologic features of malakoplakia (eg, hypercellularity, inflammation, and mineralization of Michaelis-Gutmann bodies) lead to specific features on imaging, such as marked diffusion restriction, heterogeneous enhancement, calcification, and increased attenuation on nonenhanced computed tomography. These features may help differentiate malakoplakia from other more common lesions that occur in this location, especially if present in an immunocompromised patient.
Asunto(s)
Colangiopancreatografia Retrógrada Endoscópica , Enfermedades Duodenales/diagnóstico , Malacoplasia , Imagen Multimodal , Enfermedades Pancreáticas/diagnóstico , Anciano , Biopsia , Diagnóstico Diferencial , Enfermedades Duodenales/inmunología , Enfermedades Duodenales/terapia , Endosonografía , Humanos , Huésped Inmunocomprometido , Imagen por Resonancia Magnética , Masculino , Enfermedades Pancreáticas/inmunología , Enfermedades Pancreáticas/terapia , Valor Predictivo de las Pruebas , Tomografía Computarizada por Rayos XAsunto(s)
Enfermedades Autoinmunes/complicaciones , Colitis Ulcerosa/complicaciones , Enfermedades Duodenales/diagnóstico por imagen , Enfermedades Duodenales/inmunología , Inmunoglobulina G/sangre , Enfermedades Autoinmunes/inmunología , Enfermedades Duodenales/complicaciones , Enfermedades Duodenales/patología , Endoscopía Gastrointestinal , Endosonografía , Humanos , Inmunoglobulina G/metabolismo , Masculino , Persona de Mediana Edad , Células Plasmáticas/inmunología , Células Plasmáticas/metabolismoRESUMEN
AIM: To assess the evolution of duodenal lymphocytosis (DL), a condition characterized by increased intraepithelial lymphocytes (IELs), over 2 years of follow-up. METHODS: Consecutive patients undergoing upper endoscopy/histology for abdominal pain, diarrhea, weight loss, weakness or other extraintestinal features compatible with celiac disease (CD) were included. Evaluation of IELs infiltrate in duodenal biopsy samples was carried out by CD3-immunohistochemistry and expressed as number of positive cells/100 enterocytes. Diagnostic agreement on the IELs count was tested by calculating the weighted k coefficient. All patients underwent serological detection of autoantibodies associated with CD: IgG and IgA anti-tissue transglutaminase and endomysium. Each patient underwent further investigations to clarify the origin of DL at baseline and/or in the course of 2 years of follow-up every six months. Autoimmune thyroiditis, intestinal infections, parasitic diseases, bacterial intestinal overgrowth, hypolactasia and wheat allergy were detected. Colonoscopy and enteric magnetic resonance imaging were performed when necessary. Risk factors affecting the final diagnosis were detected by multinomial logistic regression and expressed as OR. RESULTS: Eighty-five patients (16 males, 69 females, aged 34.1 ± 12.5 years) were followed up for a mean period of 21.7 ± 11.7 mo. At baseline, endoscopy/duodenal biopsy, CD3 immunohistochemistry revealed: > 25 IELs/100 enterocytes in 22 subjects, 15-25 IELs in 37 and < 15 IELs in 26. They all had negative serum anti-transglutaminase and anti-endomysium, whilst 5 showed IgG anti-gliadin positivity. In the course of follow-up, 23 developed CD seropositivity and gluten sensitivity (GS) was identified in 19. Other diagnoses were: 5 Helicobacter pylori infections, 4 jejunal Crohn's disease, 1 lymphocytic colitis and 1 systemic sclerosis. The disease in the remaining 32 patients was classified as irritable bowel syndrome because of the lack of diagnostic evidence. At multivariate analysis, the evolution towards CD was associated with an IELs infiltrate > 25 (OR = 1640.4) or 15-25 (OR = 16.95), human leukocyte antigen (HLA) DQ2/8 (OR = 140.85) or DQA1*0501 (OR = 15.36), diarrhea (OR = 5.56) and weakness (OR = 11.57). GS was associated with IELs 15-25 (OR = 28.59), autoimmune thyroiditis (OR = 87.63), folate deficiency (OR = 48.53) and diarrhea (OR = 54.87). CONCLUSION: DL may have a multifactorial origin but the IELs infiltrate and HLA are strong predictive factors for CD development and a clinical diagnosis of GS.
Asunto(s)
Enfermedad Celíaca/diagnóstico , Enfermedades Duodenales/diagnóstico , Duodeno/patología , Hipersensibilidad a los Alimentos/diagnóstico , Glútenes/efectos adversos , Mucosa Intestinal/patología , Linfocitos/patología , Linfocitosis/diagnóstico , Adulto , Autoanticuerpos/sangre , Biomarcadores/análisis , Biopsia , Complejo CD3/análisis , Enfermedad Celíaca/inmunología , Enfermedad Celíaca/patología , Distribución de Chi-Cuadrado , Colonoscopía , Progresión de la Enfermedad , Enfermedades Duodenales/inmunología , Enfermedades Duodenales/patología , Duodenoscopía , Duodeno/inmunología , Femenino , Estudios de Seguimiento , Hipersensibilidad a los Alimentos/inmunología , Hipersensibilidad a los Alimentos/patología , Glútenes/inmunología , Antígenos HLA/análisis , Humanos , Inmunohistoquímica , Mucosa Intestinal/inmunología , Modelos Logísticos , Linfocitos/inmunología , Linfocitosis/inmunología , Linfocitosis/patología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Análisis Multivariante , Oportunidad Relativa , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Pruebas Serológicas , Factores de Tiempo , Adulto JovenRESUMEN
AIM: To study the clinical features of inflammatory and atrophic changes (IAls) in the gastroduodenal zone (GDZ) in people with varying severity of chronic heart failure (CHF) associated with coronary artery disease (CAD) and to determine gastric secretion, local microcirculation, and the presence of Helicobacter pylori. SUBJECTS AND METHODS: Seventy-four patients with CHF and gastric duodenal (GD) IAls who were divided into 2 groups according to its severity were examined. The specific features of impaired gastric secretory function and blood flow in the GD mucosa and its contamination with H. pylori were elucidated. RESULTS: GD IAls were ascertained to be mainly focal in the patients with Stages I-Ila CHF and focal or diffuse in those with Stages IIb-III. According the clinical findings, these changes were generally shown in the concurrence of transient and unstable (in early- stage circulatory insufficiency) and prolonged and persistent (during severe congestive events) phenomena. The development of IAls in the GDZ was linked to its thrombohemorrhagic microcirculatory disorders, the severity of which increased as the symptoms of CHF progressed. In Stages I-Ila circulatory insufficiency, this was accompanied by the normal activity of acid-peptic factor, by the decreased production gastromucoproteins, and, in 58.3% of cases, by H. pylori. The patients with Stages IIb-III showed the suppressed production of all constituents of gastric secretion and H. pylori in 63.2% of cases. CONCLUSION: The clinical manifestations and mechanisms of GD IAIs in CHF associated with CAD have a number of substantial differences in relation to its severity, which should be kept in mind when elaborating therapeutic and diagnostic measures.
Asunto(s)
Enfermedad de la Arteria Coronaria , Enfermedades Duodenales/patología , Insuficiencia Cardíaca , Gastropatías/patología , Anciano , Enfermedad Crónica/epidemiología , Comorbilidad , Enfermedad de la Arteria Coronaria/epidemiología , Enfermedades Duodenales/inmunología , Enfermedades Duodenales/microbiología , Femenino , Insuficiencia Cardíaca/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Gastropatías/inmunología , Gastropatías/microbiologíaRESUMEN
BACKGROUND: Duodenal intraepithelial lymphocytosis (D-IEL) is an early marker for celiac disease (CD). However, the majority of cases are due to non-CD-related conditions. GOALS: To identify the predictors of CD when presented with D-IEL. METHODS: A total of 215 adult patients with D-IEL had undergone prospective and systematic evaluation for CD and other recognized associations.The gold-standard diagnosis of CD was based upon the presence of HLA-DQ2 and/or DQ8, persistence or progression of D-IEL following a gluten challenge, followed by symptomatic improvement on a gluten-free diet.Binary logistic regression models, adjusting for age and sex, were subsequently performed to compare presenting variables between CD and non-CD cases, and to determine their sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). RESULTS: CD was diagnosed in 48 cases (22%) and non-CD in 167 cases (78%). There was no statistical difference in baseline demographics, clinical symptoms (ie, diarrhea, weight loss, abdominal pain), anemia, or hematinics between the CD and non-CD group.Patients with CD, in comparison with non-CD, were significantly more likely to have a positive family history of CD (21% vs. 3.6%, OR 6.73; PPV 62.5%, NPV 81%, specificity 96.4%), positive HLA-DQ status (100% vs. 49.1%; PPV 36.4%, NPV 100%, specificity 50.9%), and presence of endomysial antibody (EMA) (48% vs. 0%; PPV 100%, NPV 87%, specificity 100%); all P≤0.001.A normal tissue transglutaminase antibody (TTG) level was seen in 29.2% CD and 83.2% non-CD cases (OR 0.084, P<0.001; PPV 9.2%). There was no difference in the prevalence of TTG levels 1 to 2×upper limit of normal (ULN) between the groups (29.2% CD vs. 14.4% non-CD; PPV 33% to 38%). However, TTG levels between 3 and 20×ULN were significantly more prevalent in the CD group (33.3% vs. 2.4%, PPV 66.6% to 89%), whereas a TTG>20×ULN was exclusive to CD (8.3%, P<0.001, PPV 100%). CONCLUSIONS: In the setting of D-IEL, only the presence of a positive EMA or TTG>20×ULN at the outset can be used to make an immediate diagnosis of CD. Gastrointestinal symptoms, family history, anemia, or other celiac serology results do not reliably distinguish CD from non-CD without further investigations.
Asunto(s)
Enfermedad Celíaca/diagnóstico , Enfermedades Duodenales/diagnóstico , Mucosa Intestinal/patología , Linfocitosis/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Autoanticuerpos/sangre , Biomarcadores/sangre , Enfermedad Celíaca/sangre , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/inmunología , Dieta Sin Gluten , Enfermedades Duodenales/inmunología , Femenino , Glútenes/inmunología , Glútenes/metabolismo , Antígenos HLA-DQ/sangre , Humanos , Linfocitosis/inmunología , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios Prospectivos , Sensibilidad y Especificidad , Transglutaminasas/sangreAsunto(s)
Ampolla Hepatopancreática/patología , Enfermedades del Conducto Colédoco/inmunología , Enfermedades Duodenales/inmunología , Anciano , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/inmunología , Enfermedades del Conducto Colédoco/patología , Enfermedades Duodenales/patología , Endoscopía Gastrointestinal , Humanos , Inmunoglobulina G/sangre , Masculino , Células Plasmáticas/inmunologíaAsunto(s)
Enfermedades Duodenales/terapia , Mucosa Gástrica/fisiopatología , Hemorragia Gastrointestinal/inducido químicamente , Cardiopatías/tratamiento farmacológico , Gastropatías/terapia , Anticoagulantes/efectos adversos , Enfermedades Duodenales/diagnóstico , Enfermedades Duodenales/inmunología , Mucosa Gástrica/inmunología , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/inmunología , Infecciones por Helicobacter/terapia , Humanos , Gastropatías/diagnóstico , Gastropatías/inmunologíaAsunto(s)
Aneurisma de la Aorta Abdominal/cirugía , Rotura de la Aorta/cirugía , Aortitis/inmunología , Enfermedades Duodenales/inmunología , Procedimientos Endovasculares/efectos adversos , Inmunoglobulina G/análisis , Fístula Intestinal/inmunología , Fístula Vascular/inmunología , Humanos , MasculinoRESUMEN
PURPOSE: To report a rare and complicated case of immunoglobulin (Ig) G4-related periaortitis involving both the aortic wall and the retroperitoneum without aneurysmal formation. CASE REPORT: A 79-year-old man with IgG4-related periaortitis suffered aortic rupture despite a normal caliber aorta after 6 months of steroid therapy (20 mg/d). Endovascular repair with an aortic cuff sealed the rupture. Steroid therapy was halted 2 weeks later due to infection. Four months later, a biopsy during esophagogastroduodenoscopy to investigate gastrointestinal bleeding suggested a relapse of IgG4-RD in the duodenum. Subsequent aortoduodenal fistula formation proved fatal. Generally, IgG4-related periaortitis does not result in such complications due to the absence of aneurysm formation and a thick aortic wall. CONCLUSIONS: Our report highlights a rare case of IgG4-related periaortitis where complications resulted following steroid therapy and surgical intervention, emphasizing the difficulties in dealing with IgG4-related cardiovascular lesions.
Asunto(s)
Aneurisma de la Aorta Abdominal/cirugía , Rotura de la Aorta/cirugía , Aortitis/inmunología , Enfermedades Duodenales/inmunología , Procedimientos Endovasculares/efectos adversos , Inmunoglobulina G/análisis , Fístula Intestinal/inmunología , Fístula Vascular/inmunología , Anciano , Aneurisma de la Aorta Abdominal/diagnóstico , Aneurisma de la Aorta Abdominal/inmunología , Rotura de la Aorta/diagnóstico , Rotura de la Aorta/inmunología , Aortitis/complicaciones , Aortitis/diagnóstico , Aortitis/tratamiento farmacológico , Aortografía/métodos , Biopsia , Implantación de Prótesis Vascular , Enfermedades Duodenales/diagnóstico , Endoscopía Gastrointestinal , Infecciones por Escherichia coli/inmunología , Infecciones por Escherichia coli/microbiología , Resultado Fatal , Hemorragia Gastrointestinal/inmunología , Humanos , Huésped Inmunocomprometido , Fístula Intestinal/diagnóstico , Masculino , Factores de Riesgo , Esteroides/efectos adversos , Factores de Tiempo , Tomografía Computarizada por Rayos X , Fístula Vascular/diagnósticoRESUMEN
Diffuse nodular lymphoid hyperplasia (DNLH) of the intestine is an extremely rare lymphoproliferative disorder of uncertain etiology. Typically, numerous polypoid nodules composed of hyperplastic benign lymphoid tissue are present in the small and/or large intestinal mucosa. DNLH has been observed in association with common variable immunodeficiency (CVID). A 38-years-old man was admitted to our clinic due to dyspeptic complaints. An upper gastrointestinal system endoscopic examination revealed DNLH in the duodenum. A biopsy specimen showed the presence of nodular lymphoid hyperplasia and a Giardia lamblia infection in the duodenum. CVID was suspected, and the diagnosis was established by demonstrating a significant reduction in the serum gamma-globulin levels. DNLH is a rare benign condition with regards to diagnosis and treatment of unknown etiology. In patients with DNLH, screening for the immune deficiencies is being important in addition to histopathological examinations.
Asunto(s)
Inmunodeficiencia Variable Común/diagnóstico , Enfermedades Duodenales/diagnóstico , Enfermedades Duodenales/inmunología , Giardiasis/diagnóstico , Giardiasis/inmunología , Trastornos Linfoproliferativos/diagnóstico , Trastornos Linfoproliferativos/inmunología , Adulto , Inmunodeficiencia Variable Común/inmunología , Diagnóstico Diferencial , Humanos , Masculino , Enfermedades Raras/diagnóstico , Enfermedades Raras/inmunologíaRESUMEN
BACKGROUND: Evaluation of intraepithelial duodenal lymphocytosis (IDL) is important in celiac disease (CD). There is no established cut-off value for increased number of IELs in the bulb.We therefore investigated the relation between IEL counts in the bulb and duodenal specimens in non-celiac subjects. METHODS: The number of CD3+ IELs was determined in specimens from the second part of the duodenum and from the bulb in 34 non-celiac subjects. The numbers of IELs in the villus tip and sides were counted and the quotient tip/side was calculated. HLA DQ2/DQ8 and serum antibodies against transglutaminase were analysed. RESULTS: The mean number of IELs per 100 enterocytes (95% CI) in specimens was 14.7 (11.8-17.6) in the bulb, and 21.2 (17.0-25.5) in the second part of the duodenum (p<0.01). There was no difference in IEL count or distribution comparing patients carrying or lacking HLA DQ2/DQ8. CONCLUSIONS: IEL count in non-celiac, HLA DQ2/DQ8 positive or negative patients is significantly lower in the bulb than in the second part of the duodenum. These findings implicate that the site of biopsy should be taken into account when considering duodenal lymphocytosis.
Asunto(s)
Complejo CD3/metabolismo , Enfermedades Duodenales/inmunología , Linfocitos/metabolismo , Linfocitosis/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades Duodenales/patología , Duodeno/citología , Duodeno/inmunología , Duodeno/metabolismo , Epitelio/inmunología , Femenino , Proteínas de Unión al GTP , Genotipo , Antígenos HLA-DQ/genética , Humanos , Inmunoglobulina A/sangre , Recuento de Linfocitos , Linfocitosis/patología , Masculino , Persona de Mediana Edad , Proteína Glutamina Gamma Glutamiltransferasa 2 , Transglutaminasas/inmunologíaRESUMEN
Most primary aortoduodenal fistulas occur in the presence of an aortic aneurysm, which can be part of immunoglobulin G4 (IgG4)-related sclerosing disease. We present a case who underwent endovascular grafting of an aortoduodenal fistula associated with a high serum IgG4 level. A 56-year-old male underwent urgent endovascular reconstruction of an aortoduodenal fistula. The patient received antibiotics and other supportive therapy, and the postoperative course was uneventful, however, elevated levels of serum IgG, IgG4 and C-reactive protein were noted, which normalized after the introduction of steroid therapy. Control computed tomography angiography showed no endoleaks. The primary aortoduodenal fistula may have been associated with IgG4-related sclerosing disease as a possible complication of IgG4-related inflammatory aortic aneurysm. Endovascular grafting of a primary aortoduodenal fistula is an effective and minimally invasive alternative to standard surgical repair.
Asunto(s)
Aneurisma de la Aorta Abdominal/inmunología , Enfermedades de la Aorta/inmunología , Enfermedades Duodenales/inmunología , Inmunoglobulina G/sangre , Fístula Intestinal/inmunología , Antibacterianos/uso terapéutico , Aneurisma de la Aorta Abdominal/sangre , Aneurisma de la Aorta Abdominal/diagnóstico por imagen , Aneurisma de la Aorta Abdominal/cirugía , Enfermedades de la Aorta/sangre , Enfermedades de la Aorta/diagnóstico por imagen , Enfermedades de la Aorta/cirugía , Aortografía/métodos , Biomarcadores/sangre , Enfermedades Duodenales/sangre , Enfermedades Duodenales/diagnóstico por imagen , Enfermedades Duodenales/cirugía , Procedimientos Endovasculares , Humanos , Fístula Intestinal/sangre , Fístula Intestinal/diagnóstico por imagen , Fístula Intestinal/cirugía , Masculino , Persona de Mediana Edad , Esteroides/uso terapéutico , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Regulación hacia ArribaRESUMEN
BACKGROUND: The clinical significance of lymphocytic duodenosis remains unclear. AIM: To prospectively assess the aetiology of lymphocytic duodenosis and the patterns of clinical presentation. METHODS: Ninety consecutive patients with lymphocytic duodenosis and clinical symptoms of the coeliac disease spectrum were prospectively included. All subjects underwent serological testing and HLA genotyping for coeliac disease, assessment of Helicobacter pylori infection, and parasite stool examination. Intake of non-steroidal anti-inflammatory drugs was also recorded. The final aetiology of lymphocytic duodenosis was evaluated on the basis of the long-term response to specific therapy. RESULTS: More than one initial potential aetiology was observed in 44% of patients. The final diagnosis was gluten-sensitive enteropathy alone or associated with Helicobacter pylori infection in 43.3%, Helicobacter pylori infection (without gluten-sensitive enteropathy) in 24.4%, non-steroidal anti-inflammatory drugs intake in 5.5%, autoimmune disease in 3.3%, and parasitic infection in 2.2%. Among first degree relatives and patients with chronic diarrhoea, the most common final diagnosis was gluten-sensitive enteropathy. In contrast, in the group presenting with chronic dyspepsia the most common diagnosis was Helicobacter pylori infection ('Diarrhoea' vs 'Dyspepsia' groups, p=0.008). CONCLUSIONS: Lymphocytic duodenosis is often associated with more than one potential initial aetiology. Clinical presentation may be useful to decide the initial therapeutic approach with these patients.
Asunto(s)
Enfermedad Celíaca/tratamiento farmacológico , Enfermedades Duodenales/etiología , Infecciones por Helicobacter/complicaciones , Linfocitos , Adulto , Antiinflamatorios no Esteroideos/efectos adversos , Enfermedades Autoinmunes/complicaciones , Infecciones por Blastocystis/complicaciones , Complejo CD3/metabolismo , Enfermedad Celíaca/sangre , Enfermedad Celíaca/complicaciones , Enfermedades Duodenales/inmunología , Enfermedades Duodenales/patología , Femenino , Proteínas de Unión al GTP , Genotipo , Antígenos HLA-DQ/genética , Helicobacter pylori , Humanos , Recuento de Linfocitos , Linfocitos/metabolismo , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Proteína Glutamina Gamma Glutamiltransferasa 2 , Transglutaminasas/inmunologíaAsunto(s)
Enfermedades Duodenales/complicaciones , Enfermedades Duodenales/patología , Fórmulas Infantiles , Tejido Linfoide/patología , Hipersensibilidad a la Leche/complicaciones , Hipersensibilidad a la Leche/diagnóstico , Enfermedades Duodenales/inmunología , Femenino , Hematemesis/etiología , Humanos , Inmunoglobulina E/sangre , Lactante , Masculino , Hipersensibilidad a la Leche/sangre , Estudios RetrospectivosRESUMEN
OBJECTIVES: Recent studies have shown that postinfectious functional dyspepsia (FD) symptoms may persist after elimination of gastrointestinal (GI) infection as well as postinfectious irritable bowel syndrome accompanying colonic inflammation. However, it is unclear whether intestinal chronic inflammation can contribute to clinical symptoms of certain FD patients such as postinfectious FD. To determine the relationship between local inflammation of the duodenum and clinical symptoms, we evaluated the infiltration of several phenotypes of duodenal inflammatory cells as well as gastric motility using (13)C urea breath test in postinfectious FD patients. METHODS: We enrolled 136 consecutive patients diagnosed with FD according to Rome III criteria, and 20 healthy controls, after upper GI endoscopy. Gastric motility was evaluated by gastric emptying time (T-max) using the (13)C-acetate breath test. Upper abdominal symptoms including epigastric pain, epigastric burning, postprandial fullness, abdominal distension, and early satiety were assessed by questionnaire scores. We obtained biopsy specimens from the stomach and duodenum during upper GI endoscopy. Histological gastritis and duodenitis were assessed as mild, moderate, or severe according to previously described criteria. Characteristics of inflammatory cells and neuroendocrine cells were determined immunohistochemically with antibodies to CD3, CD68, CCR2, Vdelta1 TCR, and serotonin. RESULTS: Endoscopic duodenitis was observed in only 5.7% of postinfectious FD patients. However, the rates of histological duodenitis in duodenal biopsies of postinfectious FD patients were 17% for mild, 26% for moderate, and 57% for severe grades of duodenitis. The degree of histological duodenitis of postinfectious FD patients was significantly greater than that of healthy volunteers. There was a significant correlation between epigastric burning and the degree of duodenitis in postinfectious FD patients. There was no significant difference in histological duodenitis and T-max value in the postinfectious FD patients with or without Helicobacter pylori infection. In addition, CD68-positive cell number in postinfectious FD patients was significantly increased compared with the numbers in subjects with epigastric pain syndrome or postprandial distress syndrome and in healthy volunteers. CCR2-/CD68-double positive cell number in postinfectious FD patients was significantly (P=0.009) increased compared with those in healthy volunteers. CONCLUSIONS: Migration of inflammatory cells, in particular, duodenal CCR2-positive macrophages, may have an important function in the pathophysiology of postinfectious FD patients.
Asunto(s)
Antígenos CD/inmunología , Antígenos de Diferenciación Mielomonocítica/inmunología , Enfermedades Duodenales/inmunología , Enfermedades Duodenales/fisiopatología , Dispepsia/inmunología , Eosinófilos/inmunología , Gastritis/inmunología , Gastritis/fisiopatología , Mucosa Intestinal/fisiopatología , Receptores CCR2/inmunología , Análisis de Varianza , Biopsia , Estudios de Casos y Controles , Movimiento Celular , Enfermedades Duodenales/microbiología , Dispepsia/microbiología , Dispepsia/fisiopatología , Endoscopía Gastrointestinal , Femenino , Vaciamiento Gástrico , Gastritis/microbiología , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Humanos , Inmunohistoquímica , Masculino , Estadísticas no Paramétricas , Encuestas y CuestionariosRESUMEN
BACKGROUND: Cytomegalovirus (CMV) is a common pathogen affecting the gastrointestinal tract in patients with AIDS. We report a case of CMV-induced pseudotumor of the duodenum in a patient with AIDS and review other reported cases of CMV-induced pseudotumors in the gastrointestinal tract. CMV-induced pseudotumor in patients with AIDS is an exceptionally rare clinical entity, and to our knowledge no reports have previously summarized this clinical entity. METHODS: All previous cases included in our literature review were found using a PubMed search (1980-November 2008) of the English-language medical literature applying the terms 'CMV infection', 'inflammatory mass', 'pseudotumor', and 'gastrointestinal tract'. The references cited in these articles were examined to identify additional reports. RESULTS: Although CMV-induced duodenitis has been described in patients with HIV infection, to our knowledge CMV-induced pseudotumor of the duodenum has not been previously reported in the literature. We describe the first case of an AIDS patient with CMV pseudotumor responding to oral treatment with valganciclovir with complete resolution of the CMV mass. Among reports of non-duodenal pseudotumor reported in the English literature, we found only 14 cases of CMV-induced gastrointestinal pseudotumors in HIV-positive patients. The clinical manifestations, pathologic findings of the CMV pseudotumors, as well as the treatment and outcome of these HIV patients are reviewed. CONCLUSION: CMV pseudotumor should be included in the differential diagnosis of gastrointestinal mass lesions in AIDS patients and in other immunocompromised patients. The tumor often responds to antiviral therapy, but resolution of a CMV mass as a result of oral antiviral therapy has not been previously described. Since pseudotumors secondary to CMV often respond to medical treatment, it is important that the physicians treating severely immunocompromised patients are aware of this entity.